Purpose: Cryoablation is done in select patients with pT1b nonmetastatic renal cell carcinoma without convincing proof of efficacy. Our aim was to test for differences in the cancer specific mortality rate for cryoablation and partial nephrectomy in T1b nonmetastatic renal cell carcinoma cases. Materials and Methods: In the 2004 to 2015 SEER (Surveillance, Epidemiology, and End Results) database we identified 5,763 patients with a T1b tumor treated with cryoablation or partial nephrectomy. Modeling relied on multivariable logistic regression models predicting cryoablation vs partial nephrectomy. After 1:2 ratio propensity score matching between patients treated with cryoablation vs partial nephrectomy we used cumulative incidence plot and competing risks regression to test differences in cancer specific mortality and other cause mortality rates. Results: Relative to the 5,521 patients who underwent partial nephrectomy the 242 treated with cryoablation were older, had smaller tumors and more frequently harbored unclassified renal cell carcinoma of low or unknown grade. Median followup was 38 months. In multivariable logistic regression models predicting cryoablation vs partial nephrectomy more advanced patient age was an independent predictor (OR 1.03; p[0.007). After propensity score matching and other cause mortality adjustment the 5-year cancer specific mortality rate was 2.5-fold higher after cryoablation than after partial nephrectomy (p[0.03). Conversely after propensity score matching and cancer specific mortality adjustment the 5-year other cause mortality rate was similar to that of partial nephrectomy after cryoablation (HR 1.45, p[0.12). The major limitation of this study was the lack of recurrence and metastatic progression data. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number. ).
IN the contemporary English language literature 9 studies have described local tumor ablation using cryoablation or radio frequency ablation in patients with T1b nmRCC. 1e9 Of those articles 4 focused on cryoablation, 1,2,4,5 4 were on radio frequency ablation 6e9 and 1 compared cryoablation vs radio frequency ablation. 3 These reports indicate that cryoablation is performed in patients with T1b nmRCC even without endorsement from guidelines committees such as those of the AUA (American Urological Association) 10 or the EAU (European Association of Urology). 11 To address the need for more evidence we performed a population based comparison between cryoablation and PN in patients with T1b RCC. Our main end point was defined as CSM. We hypothesized that cryoablation may be associated with less favorable CSM outcomes compared to those of PN.
MATERIALS AND METHODS

Data Source and Patient Selection
Using the SEER database 12 from 2004 to 2015 we focused on patients 18 years old or older with T1b histologically confirmed nmRCC (ICD-O site codes C64.9) who underwent cryoablation (surgery code 13 and 23), radio frequency ablation (surgery code 15) or PN (surgery code 30) as primary treatment ( fig. 1 ). Death was defined according to the SEER mortality code as CSM (death from RCC) or OCM (death from any other cause). All autopsy or death certificate cases and those with missing followup data were excluded from study. These selection criteria yielded 5,763 assessable patients.
Statistical Analyses
Descriptive statistics included the frequency and proportion for categorical variables. The mean, median and range are reported for continuously coded variables. We applied the chi-square test to find the statistical significance of differences in proportions. The t-test and the Kruskal-Wallis test were used to examine the statistical significance of mean and median differences.
In the main study cohort of 242 cryoablation and 5,521 PN cases we fitted multivariable logistic regression models predicting the use of cryoablation vs PN. Covariates consisted of patient age (continuous), gender (female vs male), ethnicity (Caucasian vs African American vs Asian vs other), educational status (first vs second, third and fourth quartiles), socioeconomic status (first vs second, third and fourth quartiles), marital status (married vs never married vs previously married vs unknown), population density by patient residence type (rural vs urban) and diagnosis year (2004 to 2009 vs 2010 to 2015).
Subsequently in the main study cohort we relied on 1:2 PS matching according to the nearest neighbor, 13 which was meant to optimize the nature of the comparisons with the PN control population. The 1:2 PS matched cohort of 228 cryoablation and 434 PN cases was balanced by age, gender, ethnicity, educational status, socioeconomic status, marital status, population density by patient residence type, tumor size, tumor grade, histological type and diagnosis year. Finally, we relied on cumulative incidence plots and fitted multivariable CRR models 14 to test the effect of cryoablation vs PN on CSM and OCM. Additional multivariable adjustment was made for age, tumor size, tumor grade and histological type.
Furthermore, to maximize hypothesis testing and ensure consistent results we refitted CRR models in 4 sensitivity analyses. 1) We relied on an unmatched cohort comprising the original 242 cryoablation and 5,521 PN cases. 2) We relied on 1:4 PS matching, which resulted in a cohort of 228 cryoablation and 912 PN cases. 3) We relied on 1:2 PS matching in a subgroup of patients with complete information on histological subtype and tumor grade, including 228 treated with cryoablation and 4,117 treated with PN. In that group 1:2 PS matching resulted in a cohort of 128 cryoablation and 256 PN cases. 4) We reanalyzed the data after considering 69 patients treated with radio frequency ablation and 242 treated with cryoablation vs the 5,521 who underwent PN. We also relied on 1:2 PS matching, which resulted in a cohort of 303 local tumor ablation cases, including 238 of cryoablation and 65 of radio frequency ablation, as well as 606 PN cases.
All statistical tests were 2-sided with significance considered at p <0.05. Analyses were performed with R, version 3.4.1 (http://www.r-project.org/).
RESULTS
Cryoablation vs Partial Nephrectomy
Main Study Cohort Patient and Tumor Characteristics.
The comparison between cryoablation and PN prior to any matching relied on 242 cryoablation (4.2%) and 5,521 PN (95.8%) cases (supplementary table 1, https://www.jurology.com). Relative to patients treated with PN, those who underwent cryoablation were older (median age 71 vs 61 years, p <0.001), harbored smaller tumors (median size 46.9 vs 51.0 mm) and more frequently had an unclassified histological subtype (24.0% vs 12.4%) and low grade tumors (17.4% vs 9.0%) or unknown grade tumors (35.1% vs 14.7%, all p <0.001).
Main Study Cohort Predictive Multivariable Logistic
Regression Models. In multivariable logistic regression models predicting cryoablation vs PN in the main study cohort of 242 cryoablation and 5,521 PN cases without any matching more advanced age (OR 1.03, p[0.007), never married status (OR 1.56, p[0.02) and residence in a rural county (OR 1.33, p[0.04) independently predicted higher cryoablation rates (table 1) .
Propensity Score Matched Cumulative Incidence Plots and Multivariable Competing Risks Regression Models
Predicting Cancer Specific and Other Cause Mortality.
After 1:2 PS matching of each patient who underwent cryoablation with up to 2 treated with PN 228 and 434, respectively, were available for subsequent analyses and no statistically significant differences remained between the 2 groups (supplementary table 2, https://www.jurology.com). In the 1:2 PS matched cohort of 228 cryoablation and 434 PN cases cumulative incidence plots showed 5-year CSM rates of 7.6% vs 2.8% (p[0.02) and 5-year OCM rates of 17.9% vs 11.8% (p[0.1) in cryoablation and PN cases, respectively ( fig. 2 ).
In 
DISCUSSION
Cryoablation is recommended by the AUA 10 and EAU 11 guidelines in patients with T1a nmRCC. However, groups at single institutions have investigated cryoablation in patients with T1b nmRCC. 1, 2, 4, 5 Two high quality, comparative studies focused on cryoablation vs PN 1,2 but only 1 showed no statistically significant CSM difference between the 2 techniques (p[0.48). 1 However, evidence on cancer control outcomes after cryoablation compared to PN is scarce and exclusively applicable to centers of excellence. 1, 2 To address this limitation in generalizability we performed a comparison between cryoablation and PN using the SEER database. Our primary end point was CSM and our methodology was highly similar to that in the 2 previous tertiary care center studies. 1, 2 We postulated that differences in patient origin (the SEER database vs centers of excellence) would result in higher CSM after cryoablation vs PN than that described by Caputo et al. 1 Our study resulted in several notable findings. 1) Our population consisted of 228 patients treated with cryoablation and largely exceeded the population of the 2 previous studies in which cryoablation was compared to PN. Caputo et al focused on 31 cryoablation cases 1 and Thompson et al focused on 53. 2 Additionally, our population represented a contemporary cohort relying on patients with T1b RCC treated between 2004 and 2015. In consequence our study is comparable to 2 previous single institution studies which recruited patients diagnosed from 1999 to 2014 1 and from 2000 to 2011. 2 Moreover, in our study patient age as well as the tumor size distribution were similar to those of patients treated with cryoablation at the 2 centers of excellence. Taken together these observations validate relatively comparable selection criteria for cryoablation in the current study relative to that in the previously reported studies from centers of excellence. 1, 2 2) The main end point of our analysis was CSM. We postulated that, as recorded in the SEER database, cryoablation may be associated with a higher CSM than previously reported in the tertiary care study of Caputo et al. 1 Our findings confirmed this hypothesis, as evidenced by the 2.5-fold increase in the CSM rate after cryoablation vs PN. To account for potentially highly significant differences in patient characteristics between cryoablation and PN we relied on multiple statistical tools. We accounted for patient and tumor differences using PS matching between cryoablation and PN cases. We also performed detailed multivariable model adjustments according to patient demographics and tumor characteristics. Finally, we fitted CRR models to adjust for the confounding effect of OCM since important differences may exist according to comorbidity profiles in cryoablation vs PN cases. However, although we used statistical tools aimed at reducing the effect of biases and possible confounders, the twofold higher CSM rate after cryoablation vs PN in the main analysis is highly worrisome. This concern is further substantiated by the consistency observed in the twofold higher CSM for all 4 sensitivity analyses.
3) We also made important observations regarding patient age and the risk of OCM. In logistic regression models predicting cryoablation instead of PN more advanced age represented an independent predictor (OR 1.03, p[0.007). This implies that even after adjustment for other available characteristics patients treated with cryoablation tend to be older than patients treated with PN. This age disadvantage could potentially predispose them to a higher OCM rate. However, our CRR models focusing on OCM according to cryoablation vs PN did not identify a statistically significant difference in OCM rates between the 2 management strategies (HR 1.45, p[0.12). These observations suggest that OCM and comorbidities predisposing to OCM were relatively equally distributed between cryoablation and PN cases in the 1:2 propensity score matched cohort (p[0.12).
In consequence it is unlikely that important differences existed between cryoablation and PN cases with respect to such comorbidities. Taken together our findings suggest that cryoablation should ideally not be performed in T1b cases in clinical practice outside clinical trials or institutional protocols unless further data become available to support cryoablation safety in regard to cancer control end points relative to PN.
High quality, comparative data on the cancer control outcomes of cryoablation vs PN can only be obtained from the studies of Caputo 1 and Thompson 2 et al. However, several other groups have also addressed cryoablation in patients with T1b RCC in a less structured and uncontrolled format. 3e5 Those studies relied on even smaller sample sizes of 23 to 46 patients. Specifically Hebbadj et al reported cancer control outcomes in 27 patients with T1b RCC treated with cryoablation from 2008 to 2016 without reference to a control group. 4 Atwell et al reported survival outcomes in 46 patients with T1b RCC treated with cryoablation between 2003 and 2011, also without a reference group. 5 Finally, Hasegawa et al compared 23 cryoablation cases with 23 radio frequency ablation cases treated between 2006 and 2014, and found similar complication, local progression-free and overall survival rates for the 2 techniques. 3 However, these studies are not comparable to our study or to the studies by Caputo 1 and Thompson 2 et al due to the absence of a surgical PN reference group.
Finally, in another historical study Choueiri et al used the SEER database and focused on local tumor ablation. 15 Specifically they relied on T1 RCC cases, without T1a vs T1b substage stratification in the SEER database from 2004 to 2007. A total of 578 local tumor ablation, 4,402 PN and 10,165 radical nephrectomy cases were included. Unfortunately the local tumor ablation type was not defined as cryoablation or radio frequency ablation despite the established existence of differences in the cancer control rate between these 2 modalities. 16, 17 Finally, the reference group consisted of PN or radical nephrectomy instead of PN as in the studies by Caputo 1 and Thompson 2 et al, and the current study. Thus, the study of Choueiri et al 15 cannot be used for direct comparison with the current study or with the reports by Caputo 1 and Thompson 2 et al.
Despite the strengths of this study, the limitations include its retrospective nature, the lack of standardized specimen handling, no central pathology review and the lack of data on earlier cancer control end points such as local recurrence and disease-free survival. Moreover, information about comorbidities could not be assessed and thus we could not adjust for comorbidities. Nonetheless, we adjusted for OCM, which represents a proxy of life threating comorbidities, as well as for patient age and we relied on PS matching to maximally reduce biases. However, despite the best efforts at statistical adjustment these measures are not equivalent to a prospective randomized trial.
Lastly, the SEER database does not provide hospital information such as complications, repeat ablative procedures, hospital volume or teaching status, or tertiary care status. However, Trudeau et al found that ablative procedures are performed at low and high volume centers, representing 24.3% and 75.7% of cases, respectively. 18 Similarly Welch et al noted a shift of ablative procedures from high to low volume centers. 19 Finally, Trudeau et al reported that ablative procedures were performed at academic and nonacademic centers, representing 69% and 16% of cases, respectively. 20 Using the SEER database and the statistical method of PS matching to reduce biases intrinsic in large, population based data sets, the authors analyzed the records of 5,763 patients in whom T1b (4 to 7 cm) renal cancer was managed by cryoablation in 242 and by PN in 5,521 to determine CSM. Disparities between the groups included the observations that patients treated with cryoablation were 10 years older (age 71 vs 61 years) and had smaller tumors (4.7 vs 5.1 cm) and more patients had an unknown tumor grade (35.1% vs 14.7%). PS 1:2 matching was done to compare 128 patients treated with cryoablation to 256 treated with PN for whom complete pathological information was available. The authors found that the CSM rate in cryoablation cases was 2.5-fold higher than in PN cases. Missing information that also limits this study includes recurrencefree and disease-free survival, additional treatments and medical comorbidities.
Despite contemporary technical advances in kidney surgery and interventional radiology, as guideline committees create treatment recommendations they are hindered by deficiencies in many studies such as this. Urologists faced with a T1b tumor must carefully assess the patient using prevailing principles of oncology and medicine coupled with realistic treatment goals based on patient age and medical status. Careful surveillance in elderly and comorbidly ill patients will reduce unnecessary and potentially dangerous procedures not destined to provide meaningful life extension. PN or cryoablation should not be offered to treat an anxious patient and family under the exaggerated impression that a T1b renal mass has immediately lethal capabilities or to enthusiastically apply the new and expensive technologies now heavily marketed around the world.
